Girdin protein: A new potential distant metastasis predictor of breast cancer

Medical Oncology

Volumn 29, Issue 3, 2012, Pages 1554-1560

  Liu, Caigang ^a   Zhang, Yanjun ^a   Xu, Hong ^b   Zhang, Ruishan ^b   Li, Hua ^c   Lu, Ping ^a   Jin, Feng ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b Tumor Hospital of Liaoning Province   (China)

^c HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; Girdin protein; Metastasis; Survival

Indexed keywords

BIOLOGICAL MARKER; CERBB2 PROTEIN; ESTROGEN RECEPTOR; GIRDIN PROTEIN; KI 67 ANTIGEN; ONCOPROTEIN; PROGESTERONE RECEPTOR; PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE SPECIFIC SURVIVAL; DISTANT METASTASIS; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; POSTOPERATIVE PERIOD; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MICROFILAMENT PROTEINS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TUMOR MARKERS, BIOLOGICAL; VESICULAR TRANSPORT PROTEINS;

EID: 84871277138     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-0087-6     Document Type: Article

References (19)

1. For The International Cancer Screening Network (ICSN). Dowling EC, Klabunde C, Patnick J, Ballard-Barbash R, For the International Cancer Screening Network (ICSN). Breast and cervical cancer screening programme implementation in 16 countries. J Med Screen. 2010;17:139-46.
2. Gaffan J, Dacre J, Jones A. Educating undergraduate medical students about oncology: a literature review. J Clin Oncol. 2006; 24(12):1932-9.
3. Warner E, Hill K, Causer P, Plewes D, Jong R, Yaffe M, Foulkes WD, Ghadirian P, Lynch H, Couch F, Wong J, Wright F, Sun P, Narod SA. Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging. J Clin Oncol. 2011;29(13):1664-9.
4. Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, Nielsen TO, Gelmon K. Metastatic behavior of breast cancer subtypes. J Clin Oncol. 2010;28(20):3271-7.
5. Page K, Hava N, Ward B, Brown J, Guttery DS, Ruangpratheep C, Blighe K, Sharma A, Walker RA, Coombes RC, Shaw JA. Detection of HER2 amplification in circulating free DNA in patients with breast cancer. Br J Cancer. 2011;104(8):1342-8.
6. Wang X, Yi L, Zhu Y, Zou J, Hong Y, Zheng W. AKT signaling pathway in invasive ductal carcinoma of the breast: correlation with ERa, ERb and HER-2 expression. Tumori. 2011;97(2): 185-90.
7. Serra V, Scaltriti M, Prudkin L, Eichhorn PJ, Ibrahim YH, Chandarlapaty S, Markman B, Rodriguez O, Guzman M, Rodriguez S, Gili M, Russillo M, Parra JL, Singh S, Arribas J, Rosen N, Baselga J. PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene. 2011;30(22):2547-57.
8. Jiang P, Enomoto A, Jijiwa M, Kato T, Hasegawa T, Ishida M, Sato T, Asai N, Murakumo Y, Takahashi M. An actin-binding protein Girdin regulates the motility of breast cancer cells. Cancer Res. 2008;68(5):1310-8.
9. Garcia-Marcos M, Jung BH, Ear J, Cabrera B, Carethers JM, Ghosh P. Expression of GIV/Girdin, a metastasis-related protein, predicts patient survival in colon cancer. FASEB J. 2011;25(2): 590-9.
10. Ling Y, Jiang P, Cui SP, Ren YL, Zhu SN, Yang JP, Du J, Zhang Y, Liu JY, Zhang B. Clinical implications for Girdin protein expression in breast cancer. Cancer Invest. 2011;29(6):405-10.
11. Weng L, Enomoto A, Ishida-Takagishi M, Asai N, Takahashi M. Girding for migratory cues: roles of the Akt substrate Girdin in cancer progression and angiogenesis. Cancer Sci. 2010;101(4): 836-42.
12. Ghosh P, Garcia-Marcos M, Farquhar MG. GIV/Girdin is a rheostat that fine-tunes growth factor signals during tumor progression. Cell Adh Migr. 2011;5(3):237-48.
13. De P, Smith BR, Leyland-Jones B. Human epidermal growth factor receptor 2 testing: where are we? J Clin Oncol. 2010; 28(28):4289-92.
14. Procter M, Suter TM, de Azambuja E, Dafni U, van Dooren V, Muehlbauer S, Climent MA, Rechberger E, Liu WT, Toi M, Coombes RC, Dodwell D, Pagani O, Madrid J, Hall M, Chen SC, Focan C, Muschol M, van Veldhuisen DJ, Piccart-Gebhart MJ. Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. J Clin Oncol. 2010;28(21):3422-8.
15. Isakoff SJ, Baselga J. Trastuzumab-DM1: building a chemotherapy-free road in the treatment of human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2011; 29(4):351-4.
16. Garrett JT, Olivares MG, Rinehart C, Granja-Ingram ND, Sánchez V, Chakrabarty A, Dave B, Cook RS, Pao W, McKinely E, Manning HC, Chang J, Arteaga CL. Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc Natl Acad Sci USA. 2011;108(12):5021-6.
17. Enomoto A, Ping J, Takahashi M. Girdin, a novel actin-binding protein, and its family of proteins possess versatile functions in the Akt and Wnt signaling pathways. Ann NY Acad Sci. 2006; 1086:169-84.
18. Penault-Llorca F, André F, Sagan C, Lacroix-Triki M, Denoux Y, Verriele V, Jacquemier J, Baranzelli MC, Bibeau F, Antoine M, Lagarde N, Martin AL, Asselain B, Roché H. Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer. J Clin Oncol. 2009;27(17):2809-15.
19. Goodson WH, Moore DH, Waldman FM. Ki-67 correlates with in vivo bromodeoxyuridine labeling index in operable breast cancer. J Clin Oncol. 2006;24(23):3809.